Daratumumab Chinese instructions

Daratumumab (Daratumumab) is an important drug used to treat multiple myeloma (Multiple Myeloma). The content of its Chinese instructions will be elaborated below:

1. Indications:

Daratumumab is a monoclonal antibody drug suitable for the following conditions:

Multiple Myeloma (Multiple Myeloma): Multiple myeloma is a malignant bone marrow tumor in which abnormal plasma cells proliferate in the bone marrow, causing bone damage, anemia, infection and other clinical symptoms. Daratumumab is commonly used to treat multiple myeloma, including treatment-naïve, relapsed, or refractory cases.

2. Mechanism of action:

TargetingCD38Receptor: Daratumumab's primary role is to target the CD38 receptor that is overexpressed on the surface of abnormal plasma cells in patients with multiple myeloma. By binding to the CD38 receptor, daratumumab triggers the immune system's attack and destruction of cancer cells, promoting apoptosis and antibody-dependent cellular cytotoxicity (ADCC), thereby reducing the number of abnormal plasma cells.

3. Pharmacology:

1.Absorption: Daratumumab is usually administered intravenously and can be rapidly distributed in the body.

2.Metabolism and excretion: The metabolism and excretion characteristics of this drug in the body have not been studied in detail.

4. Dosage and usage:

1.Treatment plan: The specific daratumumab treatment plan should be determined based on the patient’s disease stage, physical condition and doctor’s recommendations.

2.General usage: Generally, daratumumab is given as an injection and is usually administered intravenously under the supervision of medical professionals. Frequency and dosage of treatment will vary based on patient needs, typically requiring more frequent dosing during initial treatment and may be less frequent subsequently.

5. Side effects:

1.Risk of infection: Daratumumab may reduce the function of the immune system, making patients more susceptible to infections.

2.Anemia and thrombocytopenia: This may lead to anemia and thrombocytopenia, increasing fatigue and risk of bleeding.

3.Allergic reactions: During use, patients may experience allergic reactions, including fever, rash, chills, headache, shortness of breath, etc.

4.Cardiovascular problems: Some patients may experience high blood pressure or other cardiovascular problems that require regular monitoring.

5.Respiratory tract infection: Respiratory tract infection is a common discomfort during treatment.

6.Other discomforts: There are other common discomforts such as nausea, vomiting, diarrhea, headaches and musculoskeletal pain.

6. Warnings and precautions:

1.Risk of infection: Patients should pay special attention to preventing infection during treatment and avoid contact with sources of infection.

2.Anaphylaxis: Patients should be closely monitored for allergic reactions, and medical professionals should be prepared to treat possible allergic situations.

3.Cardiovascular problems: Patients with cardiovascular problems require closer monitoring during treatment.

7. Contraindications:

Hypersensitivity to daratumumab: Contraindications include patients who are allergic to this drug or its components.

8. Drug interactions:

Other drugs: Interactions may occur when used with other drugs. Therefore, doctors should evaluate other medications the patient is taking to avoid adverse interactions.

9. Medication for special groups:

1.Children and Adolescents: There are currently insufficient research data to support the use of daratumumab in children and adolescents.

2.Pregnant and lactating women: For pregnant and lactating women, the use of daratumumab should be carefully considered under the guidance of a doctor.

3.Geriatric patients: Geriatric patients may require dosage adjustments as the metabolism and excretion of the drug may vary with age.

10. Listing and price situation:

Daratumumab has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The price is about more than 5,000. Medical insurance reimbursement must meet the reimbursement conditions. For specific prices and medical insurance policies, please consult the local hospital pharmacy or medical insurance bureau. Currently, there is only the original drug of daratumumab in foreign countries. The cheaper one is the Turkish original drug, which costs around 5,000. The ingredients and efficacy are consistent with the domestic original drug.